274 related articles for article (PubMed ID: 25703419)
41. Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction - Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health.
Kim MC; Jeong MH; Sim DS; Hong YJ; Kim JH; Ahn Y; Ahn TH; Seung KB; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Hur SH; Cha KS; Oh SK; Chae JK;
Circ J; 2018 Jun; 82(7):1866-1873. PubMed ID: 29643279
[TBL] [Abstract][Full Text] [Related]
42. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
43. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
[TBL] [Abstract][Full Text] [Related]
44. Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a real-life setting: the final report (J-PLACE Final).
Ako J; Morino Y; Okuizumi K; Usami M; Nakamura M
Cardiovasc Interv Ther; 2016 Apr; 31(2):101-13. PubMed ID: 26449481
[TBL] [Abstract][Full Text] [Related]
45. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
[TBL] [Abstract][Full Text] [Related]
46. Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry.
Goldstein P; Grieco N; Ince H; Danchin N; Ramos Y; Goedicke J; Clemmensen P
Vasc Health Risk Manag; 2016; 12():143-51. PubMed ID: 27143908
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
De Servi S; Goedicke J; Schirmer A; Widimsky P
Eur Heart J Acute Cardiovasc Care; 2014 Dec; 3(4):363-72. PubMed ID: 24818952
[TBL] [Abstract][Full Text] [Related]
48. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
50. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
Brener SJ; Oldroyd KG; Maehara A; El-Omar M; Witzenbichler B; Xu K; Mehran R; Gibson CM; Stone GW
Am J Cardiol; 2014 May; 113(9):1457-60. PubMed ID: 24630789
[TBL] [Abstract][Full Text] [Related]
51. Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
Koshy A; Balasubramaniam K; Noman A; Zaman AG
Cardiovasc Ther; 2014 Feb; 32(1):1-6. PubMed ID: 24428852
[TBL] [Abstract][Full Text] [Related]
52. Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome.
Wakabayashi S; Kitahara H; Nishi T; Sugimoto K; Nakayama T; Fujimoto Y; Ariyoshi N; Kobayashi Y
Cardiovasc Interv Ther; 2018 Jul; 33(3):239-246. PubMed ID: 28608310
[TBL] [Abstract][Full Text] [Related]
53. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Verdoia M; Barbieri L; Suryapranata H; De Luca G
Platelets; 2016; 27(2):93-104. PubMed ID: 25970631
[TBL] [Abstract][Full Text] [Related]
54. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
Motovska Z; Hlinomaz O; Miklik R; Hromadka M; Varvarovsky I; Dusek J; Knot J; Jarkovsky J; Kala P; Rokyta R; Tousek F; Kramarikova P; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
Circulation; 2016 Nov; 134(21):1603-1612. PubMed ID: 27576777
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction.
Flierl U; Zauner F; Sieweke JT; Berliner C; Napp LC; Tillmanns J; Bauersachs J; Schäfer A
Thromb Haemost; 2017 Jan; 117(1):99-104. PubMed ID: 27734075
[TBL] [Abstract][Full Text] [Related]
56. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction.
Sato T; Namba Y; Kashihara Y; Tanaka M; Fuke S; Yumoto A; Saito H
J Cardiol; 2017 Jul; 70(1):35-40. PubMed ID: 27836373
[TBL] [Abstract][Full Text] [Related]
58. In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience.
Lerman TT; Zahger D; Arad J; Gilutz H; Reitblat O; Shimony A
Eur Heart J Acute Cardiovasc Care; 2016 Jun; 5(3):271-6. PubMed ID: 25904758
[TBL] [Abstract][Full Text] [Related]
59. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
[TBL] [Abstract][Full Text] [Related]
60. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
